Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
-1.98% $0.990
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 20.07 mill |
EPS: | -5.52 |
P/E: | -0.180 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 20.27 mill |
Avg Daily Volume: | 0.128 mill |
RATING 2024-03-28 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Strong Buy | |
DE: | Strong Sell | |
P/E: | Strong Buy | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.180 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.180 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.841 - 1.139 ( +/- 15.05%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-05 | Patience David | Buy | 37 468 | Employee Restricted Stock Units |
2024-03-05 | Mertz Larry Michael | Buy | 40 633 | Employee Restricted Stock Units |
2024-03-05 | Phillips Jack | Buy | 119 856 | Employee Restricted Stock Units |
2024-02-26 | Patience David | Buy | 1 000 | Common Stock |
2024-02-26 | Patience David | Sell | 350 | Common Stock |
INSIDER POWER |
---|
98.62 |
Last 97 transactions |
Buy: 52 782 846 | Sell: 375 597 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.990 (-1.98% ) |
Volume | 0.0866 mill |
Avg. Vol. | 0.128 mill |
% of Avg. Vol | 67.58 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.